Last reviewed · How we verify

NCT04682782

Intraoperative Small-dose Esketamine Infusion for Pain Control in Burn Patients

Status unknown Phase 4 Last updated 24 December 2020
What this trial tests

Phase 4 trial testing Esketamine in Burns in 26 participants. Status unknown.

Timeline
14 July 2020
Primary endpoint
30 December 2020
30 December 2020

Quick facts

Lead sponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposetreatment
Enrollment26
Start date14 July 2020
Primary completion30 December 2020
Estimated completion30 December 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

18 and older, any sex, with Burns. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aim to determine whether a small-dose esketamine infusion can be used for pain control in severe burn patients, and thereby reduce the total intra-operative opioid requirement. Secondary objectives are to determine whether this low-dose esketamine infusion will increase the stability of circulation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Esketamine

Trials testing the same drug.

Other recruiting trials for Burns

Currently open trials in the same condition.

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04682782.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing